155765-75-6

Upstream product

• 58287-77-7 N,N-diethyl-4-formylbenzamide 
• 117973-14-5 3-(tert-butyldimethylsilyloxy)phenylmagnesium bromide 
• 591-20-8 3-Bromophenol 
• 18162-48-6 tert-butyldimethylsilyl chloride 
• 65423-56-5 1-bromo-3-[(tert-butyldimethylsilyl)oxy]benzene 
• 619-66-9 4-Carboxybenzaldehyde 

Downstream Products

• 364771-91-5 4-[(1-piperazinyl)-3-O-TBDMS-benzyl]-N,N-di-ethylbenzamid 
• 155836-50-3 4-((alpha-R)-alpha-((2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl)-3-hydroxybenzyl)-N,N-diethylbenzamide 
• 150428-54-9 BWB 373 

Relevant academic research and scientific papers

OLIGOMER-DIARYLPIPERAZINE CONJUGATES

The invention relates to (among other things) oligomer-diarylpiperazine conjugates and related compounds. A conjugate of the invention, when administered by any of a number of administration routes, exhibits advantages over previously administered un-conjugated diarylpiperazine compounds.

Method of treating sexual dysfunctions with delta opioid receptor agonist compounds

Compositions and methods for treatment of sexual dysfunctions by administering to a subject a pharmaceutical composition comprising a delta opioid receptor agonist in an amount effective to delay the onset of ejaculation in the subject during sexual stimulation.

Hydroxyphenyl-piperazinyl-methyl-benzamide derivatives for the treatment of pain

Compounds of general formula I 1R1 is selected from any one of pyridinyl, thienyl, furanyl, imidazolyl, and triazolyl; where each R1 heteroaromatic ring may optionally and independently be further substituted by 1, 2 or 3 substituents selected from straight and branched C1-C6 alkyl, NO2, CF3, C1-C6 alkoxy, chloro, fluoro, bromo, and iodo. The substitutions on the heteroaromatic ring may take place in any position on said ring systems; are disclosed and claimed in the present application, as well as separate enantiomers of the compounds and salts and pharmaceutical compositions comprising the novel compounds and their use in therapy, in particular in the management of pain.

Compositions and Methods for Reducing Respiratory Depression and Attendant SIde Effects of Mu Opioid Compounds

A method of reducing, treating or preventing drug-mediated respiratory depression, muscle rigidity, or nausea/vomiting in an animal, incident to the administration to said animal of a mixed delta/mu opioid agonist or a respiratory depression-mediating dru

Compositions and methods for reducing respiratory depression

The present invention relates to, inter alia, methods and compositions for reducing, treating or preventing respiratory depression in an animal, using a compound of the formula: STR1 wherein: Ar, G, Z, R2, R3, R4, R5